BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

RXi Pharmaceuticals 

1500 West Park Drive
Suite 210
Westborough  Massachusetts  01581  U.S.A.
Phone: 508-767-3861 Fax: 508-767-3862


SEARCH JOBS










 Company News
RXi Pharmaceuticals (RXII) Reports First Quarter 2015 Financial Results And Business Highlights 5/13/2015 7:26:52 AM
RXi Pharmaceuticals (RXII) Presented Promising New Data With Self-Delivering RNAi Compounds Targeting Tyrosinase And Collagenase 5/11/2015 6:28:17 AM
RXi Pharmaceuticals (RXII) To Webcast First Quarter 2015 Financial Results On Wednesday, May 13, 2015 4/29/2015 11:44:54 AM
RXi Pharmaceuticals (RXII) Announces Upcoming Presentations At Leading Partnering And Scientific Conferences 4/27/2015 11:19:47 AM
RXi Pharmaceuticals (RXII) Receives Orphan Drug Designation For Samcyprone From The U.S. FDA For The Treatment Of Malignant Melanoma Stage IIb to IV 4/17/2015 6:18:05 AM
RXi Pharmaceuticals (RXII) Reports Fourth Quarter And Year End 2014 Financial Results And Recent Corporate Highlights 3/30/2015 1:04:40 PM
RXi Pharmaceuticals (RXII) And Mirimmune LLC Enter Into An Exclusive Licensing Agreement For RXi's Self-Delivering RNAi (sd-rxRNA) Technology To Develop Cell-Based Immunotherapies To Treat Cancer 3/27/2015 7:14:35 AM
RXi Pharmaceuticals (RXII) Reports Positive Advancements In Its Dermatology Programs At The Occasion Of The 73rd Annual Meeting Of The American Academy of Dermatology 3/23/2015 8:59:10 AM
RXi Pharmaceuticals (RXII) To Webcast Fourth Quarter And Year End 2014 Financial Results On Monday, March 30, 2015 3/16/2015 9:40:59 AM
RXi Pharmaceuticals (RXII) To Present At The 73rd Annual Meeting Of The American Academy of Dermatology 3/11/2015 9:47:12 AM
12345678910...